Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
The accelerated approval for Kymriah was based on data from the phase 2 ELARA trial.
Results showed a confirmed ORR of 60.3% including a 4.3% complete response rate and 56.0% partial response rate, with a median DOR of 14.8 months.
SFA001 blocked the progression of hepatitis B to HCC in transgenic HBX animal models